Advertisement

Corticosteroid Therapy for IgG4-Related Kidney Disease

  • Takako SaekiEmail author
Chapter

Abstract

In most patients with IgG4-related kidney disease (IgG4-RKD), corticosteroid therapy leads to a rapid improvement of renal function, radiology findings, and serological abnormalities within 1 month. Consequently, corticosteroids are often considered the first-line therapy for IgG4-RKD. However, in patients with advanced renal damage before therapy, renal function does not recover completely, and therefore early diagnosis and treatment are essential. In corticosteroid monotherapy for IgG4-RKD, a moderate dose is sufficient for induction, and recovery of renal function can be maintained for a long period on low-dose maintenance in patients for whom induction corticosteroid therapy has been successful. Unfortunately, disease relapse can occur even in patients receiving maintenance therapy.

Keywords

IgG4-RKD Therapy Corticosteroid Relapse Long-term outcome 

Notes

Acknowledgement

This work was supported in part by grants from Health and Labour Sciences Research Grants for the Study of Intractable Disease from Ministry of Health, Labor and Welfare, Japan and ‘IgG4-related Kidney Disease’ working group of the Japanese Society of Nephrology.

References

  1. 1.
    Umehara H, Okazaki K, Masaki Y. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012;22(1):1–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67(7):1688–99.CrossRefPubMedGoogle Scholar
  3. 3.
    Ohshima K, Sato Y, Yoshino T. A case of IgG4-related dacryoadenitis that regressed without systemic steroid administration. J Clin Exp Hematop. 2013;53(1):53–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Chari ST, Murray JA. Autoimmune pancreatitis, part II: the relapse. Gastroenterology. 2008;134:625–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Bang S, Chung JB. Steroid therapy for autoimmune pancreatitis. In: Kamisawa T, Chung JB, editors. Autoimmune pancreatitis. Heidelberg: Springer; 2015. p. P149–53.Google Scholar
  6. 6.
    Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58:1504–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013. III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49:961–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006;4(8):1010–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62(11):1607–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Saeki T, Kawano M, Mizushima I, et al. The clinical course of patients with IgG4-related kidney disease. Kidney Int. 2013;84(4):826–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Saeki T, Kawano M, Mizushima I, et al. Recovery of renal function after glucocorticoid therapy for IgG4-related kidney disease with renal dysfunction. Clin Exp Nephrol. 2015;4 [Epub ahead of print].Google Scholar
  13. 13.
    Saeki T, Nishi S, Imai N, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010;78(10):1016–23.CrossRefPubMedGoogle Scholar
  14. 14.
    Raissian Y, Nasr SH, Larsen CP, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol. 2011;22(7):1343–52.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kawano M, Saeki T, Nakashima H, et al. Proposal for diagnostic criteria for IgG4-related kidney disease. Clin Exp Nephrol. 2011;15(5):615–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Mizushima I, Yamada K, Fujii H, et al. Clinical and histological changes associated with corticosteroid therapy in IgG4-related tubulointerstitial nephritis. Mod Rheumatol. 2012;22(6):859–70.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kawano M, Saeki T. IgG4-related kidney disease – an update. Curr Opin Nephrol Hypertens. 2015;24:193–201.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Yamamoto M, Yajima H, Takahashi H, et al. Everyday clinical practice in IgG4-related dacryoadenitis and/or sialadenitis: results from the SMART database. Mod Rheumatol. 2015;25:199–204.CrossRefPubMedGoogle Scholar
  19. 19.
    Yoshita K, Kawano M, Mizushima I, et al. Light-microscopic characteristics of IgG4-related tubulointerstitial nephritis: distinction from non-IgG4-related tubulointerstitial nephritis. Nephrol Dial Transplant. 2012;27:2755–61.CrossRefPubMedGoogle Scholar
  20. 20.
    Arai H, Hayashi H, Takahashi K, et al. Tubulointerstitial fibrosis in patients with IgG4-related kidney disease: pathological findings on repeat renal biopsy. Rheumatol Int. 2015;35(6):1093–101.CrossRefPubMedGoogle Scholar
  21. 21.
    Deshpande V, Zen Y, Chan JKC, et al. Consensus statement on the pathology of gG4-related disease. Mod Pathol. 2012;25:1181–92.CrossRefPubMedGoogle Scholar
  22. 22.
    Notohara K. Pathology. In: Kamisawa T, Chung JB, editors. Autoimmune pancreatitis. Springer: Heidelberg; 2015. p. 23–30.Google Scholar
  23. 23.
    Alexander MP, Larsen CP, Gibson IW, et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int. 2013;83(3):455–62.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.Department of Internal MedicineNagaoka Red Cross HospitalNagaokaJapan

Personalised recommendations